作者: Sean D. Hood , Spilios V. Argyropoulos , David J. Nutt
DOI: 10.2165/00023210-200013060-00004
关键词:
摘要: Benzodiazepines have been used as anxiolytics for many years, despite well described withdrawal effects and drug interactions. Serotonergic antidepressants, which benefit from a favourable adverse effect profile do not cause dependence, are now established first-line treatments anxiety disorders. It is apparent, however, that current ideal, particularly they always produce complete recovery. Our growing knowledge of the neurobiology disorders, aided by advances in neuroimaging pharmacological challenges, has led to development other potential anxiolytics. Agents with increased specificity serotonin receptor subtypes developed, aim maximising therapeutic efficacy while minimising effects. Novel anxiolytics, such neuropeptide agonists antagonists, γ-aminobutyric acid (GABA)A partial agonists, N-methyl-D-aspartate (NMDA) neurosteroids others, currently may eventually offer alternatives available agents.